Exozymes (EXOZ) Non-Current Assets (2023 - 2026)
Exozymes (EXOZ) posted quarterly Non-Current Assets of $2.0 million for Q4 2025, down 8.22% year-over-year from $2.2 million in Q4 2024, and down 3.84% quarter-over-quarter from $2.1 million in Q3 2025.
Exozymes (EXOZ) Non-Current Assets (2023 - 2026) Analysis & Trends
Exozymes (EXOZ) has reported Non-Current Assets for 3 consecutive years, with $2.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Assets fell 8.22% year-over-year to $2.0 million; the TTM figure through Dec 2025 stood at $8.4 million (changed N/A YoY), while the FY2025 annual figure was $2.0 million, down 8.22% from the prior year.
- Non-Current Assets eased to $2.0 million in Q4 2025 per EXOZ's latest filing, from $2.1 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $2.3 million in Q4 2023 and bottomed at $2.0 million in Q4 2025.
- Historically, Non-Current Assets has averaged $2.2 million across 3 years, with a median of $2.1 million in 2024.
- On a YoY basis, Non-Current Assets climbed as much as 1.16% in 2025 and fell as far as 8.22% in 2025.
- Exozymes' Non-Current Assets stood at $2.3 million in 2023, then declined by 5.58% to $2.2 million in 2024, then retreated by 8.22% to $2.0 million in 2025.
- Business Quant data shows EXOZ's Non-Current Assets at $2.0 million in Q4 2025, $2.1 million in Q3 2025, and $2.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Exozymes | 61.53 Mn | 61.53 Mn | - | 1.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.81 Mn |
| Dec 31, 2025 | 2.03 Mn |
| Sep 30, 2025 | 2.11 Mn |
| Jun 30, 2025 | 2.15 Mn |
| Mar 31, 2025 | 2.11 Mn |
| Dec 31, 2024 | 2.21 Mn |
| Sep 30, 2024 | 2.14 Mn |
| Dec 31, 2023 | 2.34 Mn |